SPP1(+) TAM: CD8(+) T Cell Crosstalk Associates with Blocking Radiotherapy Efficacy in Lung Cancer

SPP1(+) TAM:CD8(+) T 细胞串扰与肺癌放射治疗疗效阻断相关

阅读:1

Abstract

Radiotherapy (RT) is a cornerstone treatment for non-small cell lung cancer (NSCLC), but its efficacy is often limited by immune suppression in the tumor microenvironment. In this study, we identified SPP1 as a key factor up-regulated after RT, mainly expressed by immunosuppressive macrophages. Single-cell RNA sequencing and in vivo models showed that SPP1(+) macrophages inhibit CD8(+) T cell infiltration and correlate with poor prognosis. Targeting SPP1 in macrophages enhanced RT efficacy, reduced tumor burden, and restored antitumor immunity. In summary, combining RT with SPP1(+) macrophage-targeted intervention may serve as a promising strategy to overcome immune-mediated radioresistance and enhance therapeutic efficacy in NSCLC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。